Kratom use is rising faster than regulators have resolved how to handle it
A new study published in Addiction adds a stark data point to the long-running debate over kratom in the United States. Using reports to America’s Poison Centers as a measure of exposure, researchers found that kratom-related cases climbed from 19 in 2010 to 1,242 in 2023. Severe outcomes rose as well, going from no reported cases in 2010 to 158 in 2023, with 2012 identified as the first year in which a severe outcome was reported.
Kratom is a plant with psychoactive properties. At high doses, the study notes, it can produce effects similar to opioids. The new findings suggest that its growing visibility in the US market has been accompanied by a measurable increase in serious harm, not just a broader base of use.
What the numbers show
The headline increase is large even by the standards of a fast-growing public-health issue. Researchers reported a more than 65-fold rise in kratom exposures over the study period, equivalent to a 6,500% increase. The more serious cases moved upward as well, including outcomes the authors classified as life-threatening, involving significant residual disability, or resulting in death.
The study also offers a more concrete sense of how severe some single-substance cases can become. Nearly one in seven poison-center cases involving kratom alone led to hospital admission, and one in 16 resulted in admission to a critical care unit. Those figures matter because they push the discussion beyond whether kratom is merely controversial and into the realm of measurable strain on acute care.
The authors and editors associated with the report highlighted a range of known risks. According to the study summary, kratom can be associated with seizures, irregular heart rhythms, liver damage, and breathing problems. The source text also notes that when kratom is used together with other drugs, risks may increase because kratom can interfere with metabolic pathways and potentially heighten the effects of accompanying substances.
A patchwork of state rules is producing different outcomes
One of the study’s most policy-relevant findings is the divergence among states. States with kratom bans consistently showed lower rates of exposure, severe outcomes, and health-care use than states that relied on consumer-protection approaches or had no regulation at all. That pattern will likely be read in sharply different ways by advocates of stricter controls and supporters of regulated access, but the association itself is one of the clearest takeaways in the study summary.
Senior author Ryan Feldman of the Medical College of Wisconsin said kratom is neither scheduled under the US Controlled Substances Act nor approved for medical use by the FDA, leaving states to set their own rules or, in some cases, none at all. That fragmented legal landscape has turned the states into a de facto policy laboratory, with meaningfully different approaches now tied to different reported outcomes.
For lawmakers, the difficult question is not whether kratom policy needs to be addressed, but what kind of framework best reduces harm. The study does not resolve every part of that argument. It does, however, indicate that completely unregulated environments were associated with worse outcomes than ban states in the data reviewed by the researchers.
The debate is moving from anecdote to evidence
Kratom has often occupied a murky space in US public discussion, caught between claims of traditional or therapeutic use and warnings about misuse, contamination, dependence, and acute toxicity. What this study contributes is a long-range view of a trend that is now difficult to dismiss as marginal. A substance that generated just 19 poison-center exposure reports in 2010 generated 1,242 by 2023. Severe cases, once absent from the dataset, are now appearing in substantial numbers.
That shift matters for public-health planning. Poison-center data do not capture every case in the country, but they are often among the earliest broad indicators that a consumer product or drug-related issue is scaling into a system-wide concern. In this instance, the increase is large enough to suggest that kratom is no longer a niche topic confined to online communities or specialized policy debates.
It also changes the tenor of the regulatory conversation. Legislatures across the country, the study notes, are actively debating how to regulate kratom. Those debates have tended to revolve around a familiar set of tradeoffs: whether to ban, whether to regulate for purity and labeling, or whether to leave the market mostly alone. The new data put pressure on the least restrictive position by linking looser oversight with worse reported outcomes.
Why this matters now
The most important point in the new findings may be that the growth in harms has kept pace with the growth in exposure. This is not simply a story about more people knowing the name of a plant-derived substance. It is a story about more people encountering it in ways serious enough to appear in poison-center records, with a significant subset requiring hospital or critical-care admission.
The study arrives at a moment when states are still experimenting with widely different rules. In that environment, evidence about comparative outcomes becomes especially valuable. While the underlying political fight over kratom is unlikely to disappear, the public-health baseline is becoming clearer: exposure reports are up, severe outcomes are up, and the states taking the lightest-touch approach did not come out looking safer in this analysis.
That leaves policymakers, clinicians, and consumers with a more urgent task than before. Kratom may remain legally unsettled, but the consequences tied to its rise are becoming easier to count.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
